Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 11 results.
User Information
Export Records
  1. 1.   ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1
  2. Su, Wenjing; Mukherjee, Radha; Yaeger, Rona; Son, Jieun; Xu, Jianing; Na, Na; Merna Timaul, Neilawattie; Hechtman, Jaclyn; Paroder, Viktoriya; Lin, Mika; Mattar, Marissa; Qiu, Juan; Chang, Qing; Zhao, Huiyong; Zhang, Jonathan; Little, Megan; Adachi, Yuta; Han, Sae-Won; Taylor, Barry S; Ebi, Hiromichi; Abdel-Wahab, Omar; de Stanchina, Elisa; Rudin, Charles M; Jänne, Pasi A; McCormick, Frank; Yao, Zhan; Rosen, Neal
  3. Molecular Cell. 2022, May 14;
  1. 2.   Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor
  2. Helman, Elena; Nguyen, Minh; Karlovich, Chris; Despain, Darrin; Choquette, A Karin; Spira, Alexander I; Yu, Helena A; Camidge, D Ross; Harding, Thomas C; Lanman, Richard B; Simmons, Andrew D
  3. Clinical lung cancer. 2018, Nov; 19(6): 518-530.e7.
  1. 3.   Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B
  2. Thomas, Nicholas; Glod, John; Derse-Anthony, Claudia; Baple, Emma L; Obsborne, Nigel; Sturley, Rachel; Vaidya, Bijay; Newbold, Kate; Brooke, Antonia
  3. Clinical endocrinology. 2018, May; (5): 754-756.
  1. 4.   Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo [3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple -acting angiokinase inhibition as antitumor agents
  2. Pavana, Roheeth Kumar; Choudhary, Shruti; Bastian, Anja; Ihnat, Michael A.; Bai, Ruoli; Hamel, Ernest; Gangjee, Aleem
  3. BIOORGANIC & MEDICINAL CHEMISTRY. 2017, Jan 15; 25(2): 545-556.
  1. 5.   Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296
  2. Langenkamp, E.; Zwiers, P. J.; Moorlag, H. E.; Leenders, W. P.; Croix, B. S.; Molema, G.
  3. Anti-Cancer Drugs. 2012, Feb; 23(2): 161-172.
  1. 6.   Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas
  2. Kummar, S.; Gutierrez, M. E.; Chen, A.; Turkbey, I. B.; Allen, D.; Horneffer, Y. R.; Juwara, L.; Cao, L.; Yu, Y. K.; Kim, Y. S.; Trepel, J.; Chen, H.; Choyke, P.; Melillo, G.; Murgo, A. J.; Collins, J.; Doroshow, J. H.
  3. European Journal of Cancer. 2011, May; 47(7): 997-1005.
  1. 7.   Natural products active in aberrant c-Kit signaling
  2. Henrich, C. J.; Goncharova, E. I.; Wilson, J. A.; Gardella, R. S.; Johnson, T. R.; McMahon, J. B.; Takada, K.; Bokesch, H. R.; Gustafson, K. R.
  3. Chemical Biology & Drug Design. 2007, May; 69(5): 321-330.
  1. 8.   A novel macrocyclic tetrapeptide mimetic that exhibits low- picomolar Grb2 SH2 domain-binding affinity
  2. Shi, Z. D.; Lee, K.; Liu, H. P.; Zhang, M. C.; Roberts, L. R.; Worthy, K. M.; Fivash, M. J.; Fisher, R. J.; Yang, D. J.; Burke, T. R.
  3. Biochemical and Biophysical Research Communications. 2003 310(2): 378-383.
  1. 9.   Macrocyclization in the design of Grb2 SH2 domain-binding ligands exhibiting high potency in whole-cell systems
  2. Wei, C. Q.; Gao, Y.; Lee, K.; Guo, R.; Li, B. H.; Zhang, M. C.; Yang, D. J.; Burke, T. R.
  3. Journal of Medicinal Chemistry. 2003 46(2): 244-254.
  1. 10.   Synthesis of a phosphotyrosyl analogue having X-1, X-2 and phi angles constrained to values observed for an SH2 domain-bound phosphotyrosyl residue
  2. Wang, X. Z.; Yao, Z. J.; Liu, H. P.; Zhang, M. C.; Yang, D. J.; George, C.; Burke, T. R.
  3. Tetrahedron. 2003 59(32): 6087-6093.
  1. 11.   Phosphotyrosyl mimetics in the development of signal transduction inhibitors
  2. Burke, T. R.; Lee, K.
  3. Accounts of Chemical Research. 2003 36(6): 426-433.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel